Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

ESC
Virtual
2021
Symposium
Date and time:
27.08.2021 at 13:00 - 13:45 CEST
Type:
Corporate Event
Speakers:
Matthew Cavender; Mansoor Husain; Mark Petrie;
Congress:
European Society of Cardiology (ESC)
This Novo Nordisk symposium at ESC Congress 2021 will feature speakers Dr. Matthew Cavender, Dr. Mansoor Husain and Prof. Mark Petrie. This symposium will focus on the cardiovascular effects of GLP-1RAs, from both a clinical and mechanistic perspective, and celebrate the five years of CV benefits with GLP-1RAs that started with LEADER - the first cardiovascular outcomes trial (CVOT) to demonstrate a significant reduction in CV events with a GLP-1RAs. This symposium will be followed by a live panel discussion, where audience members will have the opportunity to pose questions to the speakers.

GLP-1RAs & CV outcomes: What have we learned?

Cardiovascular effects of GLP-1RAs

GLP-1RA use in cardiology

Live panel discussion

Matthew Cavender - Speaker

Matthew Cavender

University of North Carolina, Chapel Hill, USA


Dr. Matthew A. Cavender, MD, MPH is an Assistant Professor and the Director of the Cardiology Clinical Outcomes Group and Co-Director of Cardiovascular Clinical Trials at the University of North Carolina in Chapel Hill, NC.

 

He received his medical degree from the University of Alabama School of Medicine and a Master’s of Public Health from the Harvard School of Public Health. He completed an internship and residency in Internal Medicine at Duke University in Durham, North Carolina, clinical fellowship in cardiology at the Cleveland Clinic in Cleveland, Ohio, and a research and interventional cardiology fellowship at Brigham and Women’s Hospital in Boston, Massachusetts.

 

He is clinically active as an interventional cardiologist and specializes in transcatheter therapies for patients with advanced coronary artery disease, peripheral vascular disease and valvular heart disease. He has extensive experience in clinical research studying the clinical effectiveness of clinical interventions, devices, and pharmacotherapies.  His research efforts are focused on the effectiveness of existing treatment strategies and therapies for patients with cardiovascular disease, the impact of diabetes on cardiovascular events among patients with coronary artery disease, and pharmacologic and interventional strategies to improve outcomes in patients with diabetes and atherosclerosis.

 

Dr. Cavender is a Fellow of the American College of Cardiology and member of a number of medical societies and organizations, including the American Heart Association Council of Clinical Cardiology, and the Society for Cardiovascular Angiography and Interventions. Dr. Cavender has authored numerous works on pharmacologic and interventional therapies for patients with coronary artery disease, valvular heart disease, diabetes, and myocardial infarction that have been published in peer-reviewed journals including The New England Journal of Medicine, The Lancet, Circulation and The Journal of the American College of Cardiology. He is on the editorial board of Circulation: Cardiovascular Interventions, Clinical Cardiology, and the American Heart Journal.


Read full bio
Mansoor Husain

Mansoor Husain

Ted Rogers Centre for Heart Research, Toronto, Canada


Dr Mansoor Husain is the Executive Director of the Ted Rogers Centre for Heart Research and is a Professor of Medicine at the University of Toronto.  He is an Attending Staff Cardiologist at the University Health Network. 

Dr Husain was the gold medalist in Medicine at the University of Alberta, completed his clinical training at the University of Toronto, and undertook post-doctoral training in the Program of Excellence in Cardiovascular Biology at the Massachusetts Institute of Technology. 

His current research aims to elucidate the molecular bases of cardiovascular diseases such as hypertension, atherosclerosis and heart failure, with a particular emphasis on identifying therapeutic targets involved in pathophysiology. Dr Husain’s research has improved our understanding of the cardiovascular mechanisms of glucagon-like peptide-1 and related anti-diabetic drugs.


Read full bio
Mark Petrie

Mark Petrie

University of Glasgow, Glasgow, United Kingdom


Mark Petrie is Professor of Cardiology at the University of Glasgow, Glasgow, UK. In Glasgow Royal Infirmary he runs a broad-ranging heart failure service alongside nurses and pharmacists. He also is a member of the Scottish National Advanced Heart Failure team at the Golden Jubilee National Hospital, Clydebank, UK, which he directed until 2014. 

He is in leadership positions of many trials, including STICH, REVIVED, EMPACT-MI, STEP-HF, REDUCE-LAP, Dapa-HF, PARADISE-MI, RELIEHF-HF, FINEARTS, and IRONMAN. Professor Petrie has published over 200 manuscripts, including many in journals such as the New England Journal of Medicine, The Lancet, Circulation, JACC and the European Heart Journal.

 

His clinical and research interests in diabetes and heart failure began in 2006.  He was a senior author of the 2018 European Society of Cardiology (ESC) heart failure and diabetes consensus statement, an author of the ESC NSTEMI Guidelines and a reviewer of the 2016 ESC HF Guidelines. Prof. Petrie has chaired or been a member of the clinical events committees of EMPA REG-OUTCOME, CARMELINA, CAROLINA, DELIVER as well as around 30 other trials.  


Read full bio

Related